The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer-Reference-Cited by-同舟云学术

The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer

Published:2023 Issue: Volume:34 Page:100676
ISSN:2468-2942
Container-title:Cancer Treatment and Research Communications
language:en
Short-container-title:Cancer Treatment and Research Communications

Author:

Kicken M.P.^ORCID,Kilinc H.D.,Cramer-van der Welle C.M.,Houterman S.,van den Borne B.E.E.M.,Smit A.A.J.,van de Garde E.M.W.,Deenen M.J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies;Ho;Crit. Rev. Oncol. Hematol.,2016

2. Clinical pharmacokinetics and dose optimisation of carboplatin;Duffull;Clin. Pharmacokinet.,1997

3. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support;Shen;Cancer Chemother. Pharmacol.,2002

4. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?;Ekhart;Cancer Chemother. Pharmacol.,2009

5. Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients;Sorensen;Cancer Chemother. Pharmacol.,1991

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed;Thoracic Cancer;2023-07-19